MedTrace Logo

Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)

NCT00457015 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2021-06-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of DX-88 (ecallantide) versus placebo in the treatment of moderate to severe acute attacks of hereditary angioedema.

Conditions

  • Hereditary Angioedema (HAE)

Interventions

DRUG

ecallantide

dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.

DRUG

Phosphate Buffer Saline (PBS), pH 7.0

given as three 1mL subcutaneous injections.

Sponsors & Collaborators

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-01
Primary Completion
2008-06-01
Completion
2008-06-01

Countries

  • United States
  • Canada
  • Jordan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00457015 on ClinicalTrials.gov